A Phase II, Open-label, Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener "PureLo" on Viral Load in Treatment Naïve, Genotype 1 Subjects With Chronic Hepatitis C

Trial Profile

A Phase II, Open-label, Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener "PureLo" on Viral Load in Treatment Naïve, Genotype 1 Subjects With Chronic Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Siraitia grosvenorii (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Canopus BioPharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top